Citigroup
FNCH

Citigroup’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

Citigroup’s Portfolio FNCH Stock Details FNCH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2
Closed – – 6536
2022
Q2 		$0 Sell
2
-9
-82% -$770 ﹤0.01% 6829
2022
Q1 		$2K Sell
11
-52
-83% -$12K ﹤0.01% 6118
2021
Q4 		$19K Buy
63
+34
+117% +$13K ﹤0.01% 5405
2021
Q3 		$11K Buy
29
+14
+93% +$5.97K ﹤0.01% 5452
2021
Q2 		$6K Buy
+15
New +$6.49K ﹤0.01% 5824

Other funds holding FNCH

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AMC
Avenir Management Company New York $43.8M AUM 101.91% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return
TA
TRB Advisors New York $146M AUM 3.71% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
SW
SVB Wealth Boston, Massachusetts $1.59B AUM 24.57% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Citigroup's FNCH Position: Q3 2022 in Review

Citigroup sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q3 2022, closing a stake of 2 shares.

Citigroup first reported a position in FNCH in Q2 2021 and held it in 5 quarters. The position peaked at $19K in Q4 2021. 43 funds tracked by Wall St. Rank hold FNCH as of Q3 2022.

  • Citigroup reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Citigroup sold 2 Finch Therapeutics Group, Inc. Common Stock shares in Q3 2022.
  • Citigroup first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q2 2021 and held it in 5 quarters.
  • Citigroup's Finch Therapeutics Group, Inc. Common Stock position peaked at $19K in Q4 2021.
  • 43 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q3 2022.

Based on Citigroup's 13F filing for Q3 2022, filed 10 Nov 2022.